Corbus Pharmaceuticals (CRBP) Competitors $9.00 -0.11 (-1.21%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$9.20 +0.20 (+2.17%) As of 08/7/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRBP vs. RGNX, SVRA, KMDA, CMPX, PVLA, FULC, GOSS, TECX, ETON, and AQSTShould you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include REGENXBIO (RGNX), Savara (SVRA), Kamada (KMDA), Compass Therapeutics (CMPX), Palvella Therapeutics (PVLA), Fulcrum Therapeutics (FULC), Gossamer Bio (GOSS), Tectonic Therapeutic (TECX), Eton Pharmaceuticals (ETON), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Corbus Pharmaceuticals vs. Its Competitors REGENXBIO Savara Kamada Compass Therapeutics Palvella Therapeutics Fulcrum Therapeutics Gossamer Bio Tectonic Therapeutic Eton Pharmaceuticals Aquestive Therapeutics REGENXBIO (NASDAQ:RGNX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation. Do analysts rate RGNX or CRBP? REGENXBIO presently has a consensus target price of $29.00, indicating a potential upside of 267.09%. Corbus Pharmaceuticals has a consensus target price of $49.00, indicating a potential upside of 444.44%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has more risk and volatility, RGNX or CRBP? REGENXBIO has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500. Is RGNX or CRBP more profitable? Corbus Pharmaceuticals has a net margin of 0.00% compared to REGENXBIO's net margin of -100.62%. Corbus Pharmaceuticals' return on equity of -43.65% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-100.62% -53.29% -30.84% Corbus Pharmaceuticals N/A -43.65%-39.62% Do insiders and institutionals believe in RGNX or CRBP? 88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 12.8% of REGENXBIO shares are held by insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor RGNX or CRBP? In the previous week, Corbus Pharmaceuticals had 8 more articles in the media than REGENXBIO. MarketBeat recorded 14 mentions for Corbus Pharmaceuticals and 6 mentions for REGENXBIO. Corbus Pharmaceuticals' average media sentiment score of 0.54 beat REGENXBIO's score of -0.26 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, RGNX or CRBP? Corbus Pharmaceuticals has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$83.33M4.76-$227.10M-$3.11-2.54Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-1.89 SummaryCorbus Pharmaceuticals beats REGENXBIO on 11 of the 16 factors compared between the two stocks. Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBP vs. The Competition Export to ExcelMetricCorbus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.64M$2.51B$5.48B$9.57BDividend YieldN/A1.78%4.00%4.18%P/E Ratio-1.8919.6629.8825.14Price / SalesN/A684.52440.19102.95Price / CashN/A165.0335.9458.58Price / Book0.994.198.105.59Net Income-$40.21M$31.61M$3.26B$265.48M7 Day Performance-3.33%0.95%0.65%1.22%1 Month Performance19.36%2.90%2.44%0.39%1 Year Performance-83.21%4.11%27.59%23.47% Corbus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBPCorbus Pharmaceuticals4.5039 of 5 stars$9.00-1.2%$49.00+444.4%-81.4%$111.64MN/A-1.8940Earnings ReportAnalyst ForecastAnalyst RevisionRGNXREGENXBIO3.9627 of 5 stars$8.79-1.9%$31.63+259.8%-34.4%$449.44M$83.33M-2.83370News CoverageEarnings ReportGap DownSVRASavara2.006 of 5 stars$2.66+3.1%$5.60+110.5%-34.3%$445.92MN/A-5.5420Upcoming EarningsHigh Trading VolumeKMDAKamada4.5849 of 5 stars$7.68-0.5%$13.00+69.3%+33.5%$443.94M$160.95M26.48360News CoverageUpcoming EarningsCMPXCompass Therapeutics2.9089 of 5 stars$3.20+0.6%$12.67+295.8%+208.9%$439.74M$850K-7.8020Upcoming EarningsPVLAPalvella Therapeutics2.7169 of 5 stars$39.87+3.2%$47.50+19.1%N/A$426.97M$42.81M0.00N/ANews CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionFULCFulcrum Therapeutics2.4488 of 5 stars$7.81flat$6.29-19.5%-17.9%$421.58M$80M-111.56100GOSSGossamer Bio3.9236 of 5 stars$1.98+7.6%$8.25+316.7%+114.3%$418.24M$114.70M-8.61180News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionTECXTectonic Therapeutic2.5446 of 5 stars$22.74+1.9%$80.33+253.3%+35.8%$416.77MN/A-3.11120News CoverageEarnings ReportUpcoming EarningsETONEton Pharmaceuticals2.0321 of 5 stars$15.03-2.4%$29.67+97.4%+337.2%$412.99M$39.01M-83.5020News CoverageEarnings ReportAQSTAquestive Therapeutics1.6804 of 5 stars$4.00-3.6%$10.14+153.6%+14.6%$412.21M$57.56M-6.78160 Related Companies and Tools Related Companies RGNX Alternatives SVRA Alternatives KMDA Alternatives CMPX Alternatives PVLA Alternatives FULC Alternatives GOSS Alternatives TECX Alternatives ETON Alternatives AQST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredFuturist Eric Fry says it will be a “Summer of Surge” for these three stocksWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBP Stock Alerts